Last reviewed · How we verify
Vaccination with Gardasil
Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18.
Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11, Prevention of anal cancer and other HPV-related malignancies.
At a glance
| Generic name | Vaccination with Gardasil |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Recombinant quadrivalent HPV vaccine |
| Target | Human papillomavirus (HPV) types 6, 11, 16, 18 |
| Modality | Biologic |
| Therapeutic area | Oncology / Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains virus-like particles (VLPs) derived from the major capsid protein of four HPV types. Upon administration, these VLPs trigger a humoral immune response that generates neutralizing antibodies, which prevent infection by these HPV strains. This prophylactic approach prevents HPV-related cancers and diseases including cervical cancer, anal cancer, and genital warts.
Approved indications
- Prevention of cervical cancer caused by HPV types 16 and 18
- Prevention of genital warts caused by HPV types 6 and 11
- Prevention of anal cancer and other HPV-related malignancies
Common side effects
- Injection site pain, swelling, or erythema
- Headache
- Myalgia
- Fever
- Syncope (fainting)
Key clinical trials
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (PHASE2)
- A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) (PHASE1)
- GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose (PHASE4)
- HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (PHASE3)
- Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection
- Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. (PHASE4)
- Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (PHASE4)
- Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccination with Gardasil CI brief — competitive landscape report
- Vaccination with Gardasil updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI